Oncternal Therapeutics (ONCT) News Today → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free ONCT Stock Alerts $9.00 +0.80 (+9.76%) (As of 03/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineOncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancerglobenewswire.com - March 15 at 9:00 AMNorthland Securities Keeps Their Buy Rating on Heron Therapeutics (HRTX)markets.businessinsider.com - March 13 at 1:49 PMOncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Linefinance.yahoo.com - March 10 at 3:41 PMQ4 2023 Oncternal Therapeutics Inc Earnings Callfinance.yahoo.com - March 8 at 11:39 AMOncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call Transcriptmsn.com - March 8 at 11:39 AMOncternal Therapeutics's Earnings: A Previewbenzinga.com - March 8 at 6:38 AMONCT Stock Earnings: Oncternal Therapeutics Misses EPS, Beats Revenue for Q4 2023msn.com - March 7 at 10:45 PMRecap: Oncternal Therapeutics Q4 Earningsbenzinga.com - March 7 at 5:45 PMOncternal Therapeutics: Q4 Earnings Snapshotwashingtonpost.com - March 7 at 5:45 PMOncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - March 7 at 4:01 PMOncternal Therapeutics earnings: here's what to expectmarkets.businessinsider.com - March 6 at 4:42 PMOncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - February 29 at 4:05 PMOncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wiselyfinance.yahoo.com - February 25 at 9:28 AMOncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conferencefinance.yahoo.com - February 6 at 8:35 PMOncternal Therapeutics Inc ONCTmorningstar.com - February 3 at 11:18 PMONCT Jul 2024 7.500 callca.finance.yahoo.com - January 30 at 7:36 PMONCT Apr 2024 2.500 callca.finance.yahoo.com - January 30 at 7:36 PMOncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancerfinance.yahoo.com - January 8 at 9:22 AMmarketbeat.com - January 8 at 6:02 AMOncternal Therapeutics announces a reverse stock splitmsn.com - January 4 at 12:00 PMOncternal Therapeutics Announces Reverse Stock Splitfinance.yahoo.com - January 4 at 12:00 PMOncternal Therapeutics Updates Early Disease Response Data For ONCT-808; Shares Fallnasdaq.com - December 26 at 2:16 PMOncternal Therapeutics Reports Patient Death In Mid-Stage Blood Cancer Study Treated With Second Dose Levelmsn.com - December 26 at 2:16 PMOncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphomafinance.yahoo.com - December 26 at 9:16 AMOncternal Therapeutics Stock (NASDAQ:ONCT) Dividends: History, Yield and Datesbenzinga.com - December 21 at 8:55 AMOncternal Therapeutics upgraded to Buy from Hold at Brooklinerealmoney.thestreet.com - December 4 at 3:26 PMOncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 11 at 12:00 PMBuy Rating for Oncternal Therapeutics: Promising Clinical Programs and Potential Catalystsmarkets.businessinsider.com - November 11 at 7:00 AMQ3 2023 Oncternal Therapeutics Inc Earnings Callfinance.yahoo.com - November 10 at 3:53 PMOncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 9 at 6:19 PMOncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 9 at 6:19 PMEarnings Outlook For Oncternal Therapeuticsbenzinga.com - November 8 at 3:30 PMOncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 2 at 6:08 PMOncternal Therapeutics (ONCT) Price Target Increased by 16.38% to 2.30msn.com - November 1 at 8:27 AMOncternal stock jumps 9% on FDA fast track designationmsn.com - October 26 at 3:50 PMOncternal Therapeutics Gets FDA Fast-Track on Prostate Cancer Treatmentmarketwatch.com - October 26 at 10:21 AMOncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancerfinance.yahoo.com - October 26 at 10:21 AMOncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Boardfinance.yahoo.com - October 25 at 12:38 PMOncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Boardfinance.yahoo.com - October 25 at 12:38 PMOncternal doses first patient in trial of ONCT-534 for prostate cancermsn.com - October 7 at 7:29 AMOncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancerfinance.yahoo.com - October 5 at 6:57 PMHC Wainwright & Co. Upgrades Oncternal Therapeutics (ONCT)msn.com - September 18 at 5:48 PMAnalysts Are Bullish on These Healthcare Stocks: Argenx Se (ARGX), Innate Pharma (IPHA)markets.businessinsider.com - September 18 at 7:34 AMWe're A Little Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Ratefinance.yahoo.com - September 17 at 9:56 AMCantor Fitzgerald Reiterates Oncternal Therapeutics (ONCT) Neutral Recommendationmsn.com - September 9 at 4:58 AMOncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Boardfinance.yahoo.com - September 7 at 10:16 AMQ2 2023 Oncternal Therapeutics Inc Earnings Callfinance.yahoo.com - August 12 at 3:51 PMOncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Resultsfinance.yahoo.com - August 11 at 3:07 AMWhat Wall Street expects from Oncternal Therapeutics's earningsmarkets.businessinsider.com - August 9 at 1:28 PMOncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancerfinance.yahoo.com - August 3 at 5:46 PM Get Oncternal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter. Email Address AI healthcare stock poised for 36,996% growth? (Ad)Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one... Get the name of the stock here... ONCT Media Mentions By Week ONCT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ONCT News Sentiment▼1.890.61▲Average Medical News Sentiment ONCT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ONCT Articles This Week▼11▲ONCT Articles Average Week Get Oncternal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PIRS News TFFP News QLI News KALA News LABP News GLTO News LUMO News NRSN News ITRM News BFRG News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ONCT) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.